We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
Apr 19
Hong Kong (HSI) Pharma Industry Analysis
UpdatedApr 19, 2024
DataAggregated Company Financials
Companies40
- 7D-4.5%
- 3M2.5%
- 1Y-21.8%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 4.1%, driven by Sino Biopharmaceutical declining 14%. However, the industry is down 22% over the past year. As for the next few years, earnings are expected to grow by 13% per annum.
Industry Valuation and Performance
Has the Hong Kong Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 19 Apr 2024 | HK$426.9b | HK$464.6b | HK$33.8b | 7.4x | 12.6x | 0.9x |
| Sun, 17 Mar 2024 | HK$468.3b | HK$470.3b | HK$33.3b | 7.7x | 14x | 1x |
| Tue, 13 Feb 2024 | HK$410.1b | HK$470.9b | HK$33.6b | 6.6x | 12.2x | 0.9x |
| Thu, 11 Jan 2024 | HK$468.4b | HK$472.0b | HK$33.7b | 7.8x | 13.9x | 1x |
| Sat, 09 Dec 2023 | HK$471.9b | HK$472.0b | HK$33.7b | 7.4x | 14x | 1x |
| Mon, 06 Nov 2023 | HK$489.5b | HK$469.1b | HK$31.9b | 6.9x | 15.4x | 1x |
| Wed, 04 Oct 2023 | HK$436.3b | HK$469.6b | HK$31.6b | 6.7x | 13.8x | 0.9x |
| Fri, 01 Sep 2023 | HK$429.1b | HK$454.8b | HK$30.1b | 7.6x | 14.2x | 0.9x |
| Sun, 30 Jul 2023 | HK$495.6b | HK$446.9b | HK$27.9b | 9.3x | 17.8x | 1.1x |
| Tue, 27 Jun 2023 | HK$493.8b | HK$445.9b | HK$27.6b | 9.7x | 17.9x | 1.1x |
| Thu, 25 May 2023 | HK$528.5b | HK$449.7b | HK$28.0b | 8.7x | 18.9x | 1.2x |
| Sat, 22 Apr 2023 | HK$566.9b | HK$454.4b | HK$28.9b | 9.1x | 19.6x | 1.2x |
| Mon, 20 Mar 2023 | HK$608.0b | HK$444.4b | HK$34.3b | 10.6x | 17.7x | 1.4x |
| Wed, 15 Feb 2023 | HK$616.9b | HK$447.0b | HK$35.5b | 11x | 17.4x | 1.4x |
| Fri, 13 Jan 2023 | HK$634.9b | HK$447.8b | HK$35.7b | 11.5x | 17.8x | 1.4x |
| Sun, 11 Dec 2022 | HK$609.9b | HK$442.0b | HK$34.7b | 10.3x | 17.6x | 1.4x |
| Tue, 08 Nov 2022 | HK$587.3b | HK$436.7b | HK$33.9b | 9.1x | 17.3x | 1.3x |
| Thu, 06 Oct 2022 | HK$513.7b | HK$514.3b | HK$40.0b | 8.6x | 12.8x | 1x |
| Sat, 03 Sep 2022 | HK$554.8b | HK$521.4b | HK$41.3b | 9.7x | 13.4x | 1.1x |
| Mon, 01 Aug 2022 | HK$596.4b | HK$513.1b | HK$51.9b | 8.1x | 11.5x | 1.2x |
| Wed, 29 Jun 2022 | HK$641.8b | HK$514.7b | HK$51.9b | 9.7x | 12.4x | 1.2x |
| Fri, 27 May 2022 | HK$575.9b | HK$514.9b | HK$52.3b | 8.7x | 11x | 1.1x |
| Sun, 24 Apr 2022 | HK$576.8b | HK$520.0b | HK$52.1b | 8.4x | 11.1x | 1.1x |
| Tue, 22 Mar 2022 | HK$642.0b | HK$502.6b | HK$48.0b | 8.7x | 13.4x | 1.3x |
| Thu, 17 Feb 2022 | HK$690.7b | HK$498.2b | HK$44.0b | 9.9x | 15.7x | 1.4x |
| Sat, 15 Jan 2022 | HK$751.7b | HK$496.9b | HK$43.8b | 9.9x | 17.2x | 1.5x |
| Mon, 13 Dec 2021 | HK$690.3b | HK$496.9b | HK$43.8b | 9.2x | 15.8x | 1.4x |
| Wed, 10 Nov 2021 | HK$653.5b | HK$494.8b | HK$43.3b | 9.1x | 15.1x | 1.3x |
| Fri, 08 Oct 2021 | HK$726.2b | HK$490.6b | HK$42.5b | 9.5x | 17.1x | 1.5x |
| Sun, 05 Sep 2021 | HK$816.9b | HK$489.5b | HK$42.4b | 11.6x | 19.3x | 1.7x |
| Tue, 03 Aug 2021 | HK$939.9b | HK$489.5b | HK$42.4b | 11.9x | 22.2x | 1.9x |
| Fri, 07 May 2021 | HK$986.8b | HK$463.7b | HK$30.0b | 13.9x | 32.9x | 2.1x |
Price to Earnings Ratio
32.9x
Current Industry PE
- Investors are pessimistic on the Hong Kong Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 12.7x which is lower than its 3-year average PE of 16.7x.
- The 3-year average PS ratio of 1.3x is higher than the industry's current PS ratio of 0.92x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 4.1% per year over the last three years, while revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.
Industry Comparison
How does Hong Kong Pharma compare with similar industries?
| HK Market | -1.99% | |
| Healthcare | -4.33% | |
| Pharma | -4.52% | |
| Pharma | -4.52% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1477 Ocumension Therapeutics | HK$6.12 | 4.3% +HK$173.4m | -32.3% | PS15.9x | |
| 8049 Jilin Province Huinan Changlong Bio-pharmacy | HK$1.85 | 8.2% +HK$78.4m | 6.9% | PE6.5x | |
| 6600 SciClone Pharmaceuticals (Holdings) | HK$18.04 | 0.7% +HK$73.2m | 50.3% | PE9.1x | |
| 3737 Zhongzhi Pharmaceutical Holdings | HK$1.23 | 3.4% +HK$34.5m | 1.7% | PE6x | |
| 455 Tianda Pharmaceuticals | HK$0.26 | 4.0% +HK$21.5m | 4.0% | PS1.1x |
